Oncolytics Biotech reported updated Phase 1/REO 022 efficacy data for pelareorep (Reolysin) in combination with bevacizumab and FOLFIRI in second-line RAS-mutant microsatellite-stable metastatic colorectal cancer. The update showed a median duration of response of 19.5 months and an overall response rate of 33% in KRAS-mutant MSS mCRC. The company positioned the longer response tail relative to historical standard-of-care benchmarks, and said it is discussing a potential accelerated approval pathway with the FDA. Oncolytics CEO Jared Kelly stated the durability signal supports engagement on a regulatory strategy leveraging the company’s ongoing randomized study. The trial enrolled adults with measurable disease, confirmed KRAS mutations, ECOG 0–2, and prior oxaliplatin exposure, with key exclusions including prior metastatic irinotecan/FOLFIRI use.